AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B – First Patient Dosed
AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B and First Patient Dosed AAVantgarde…
News
RIWC 2024 (Retina International World Congress)
Championing Usher Syndrome: Highlights from RIWC24 in Dublin We are thrilled to share our…
ARVO 2024 (The Association for Research in Vision and Ophthalmology Conference)
Save Sight Now Europe has been at ARVO 2024 to Champion Advances in Retinal…
AAVantgarde Bio Unveils LUCE-1 Clinical Trial Design for Usher Syndrome type 1B Gene Therapy
AAVantgarde Bio Unveils Innovative LUCE-1 Clinical Trial Design (for USH1B) at Gene Therapy Summit…
Restoring hearing loss – leading advancement in OTOF gene-related deafness
First gene therapy treatment for a hereditary form of deafness in the USA The…
UPDATE on David Gamm’s USH1B Research Program
SSNEU is collaborating with breakthrough research on gene editing for USH1B that offers hope…
Unveiling Our Mission: Introducing the Foundation in Barcelona as We Expand to Spain!
Incredible experience at the Save Sight Now Europe | Foundation Usher Syndrome presentation event…
Save Sight Now Europe Funds a program from the University of Wisconsin-Madison led by Dr. David Gamm: A Research to Study Gene Editing in Retinal Degeneration.
Save Sight Now Europe has awarded its first grant to the University of Wisconsin-Madison…
Enrolling USH1B Patients for the Uni-Rare Natural History study launched by the Foundation Fighting Blindness: A critical and necessary step for upcoming clinical trials and future therapies.
Uni-Rare is a Natural History Study of vision loss progression. It is a critical…
OHSU confirms first nonhuman primate model of Usher Syndrome.
Researchers now have a model for testing gene therapy as a treatment for a…
